Ernst Eduard, Schmidt Katja, Steuer-Vogt Miriam Katharina
Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, Exeter, United Kingdom.
Int J Cancer. 2003 Nov 1;107(2):262-7. doi: 10.1002/ijc.11386.
Mistletoe extracts are widely used in the treatment of cancer. The results of clinical trials are however highly inconsistent. We therefore conducted a systematic review of all randomised clinical trials of this unconventional therapy. Eight databases were searched to identify all studies that met our inclusion/exclusion criteria. Data were independently validated and extracted by 2 authors and checked by the 3rd according to predefined criteria. Statistical pooling was not possible because of the heterogeneity of the primary studies. Therefore a narrative systematic review was conducted. Ten trials could be included. Most of the studies had considerable weaknesses in terms of study design, reporting or both. Some of the weaker studies implied benefits of mistletoe extracts, particularly in terms of quality of life. None of the methodologically stronger trials exhibited efficacy in terms of quality of life, survival or other outcome measures. Rigorous trials of mistletoe extracts fail to demonstrate efficacy of this therapy.
槲寄生提取物被广泛用于癌症治疗。然而,临床试验结果却极不一致。因此,我们对这种非常规疗法的所有随机临床试验进行了系统评价。检索了八个数据库,以确定所有符合我们纳入/排除标准的研究。数据由两名作者独立验证和提取,并由第三名作者根据预定义标准进行核对。由于原始研究的异质性,无法进行统计合并。因此,进行了叙述性系统评价。可以纳入十项试验。大多数研究在研究设计、报告或两者方面都存在相当大的缺陷。一些较弱的研究暗示了槲寄生提取物的益处,特别是在生活质量方面。在方法学上更严谨的试验中,没有一项在生活质量、生存率或其他结局指标方面显示出疗效。对槲寄生提取物进行的严格试验未能证明这种疗法的疗效。